Introduction
In recent decades, considerable efforts have been devoted to the achievement of standardisation of measurement procedures and results in laboratory medicine. The concept of measurement traceability, which was developed in general analytical chemistry, provides probably the most important strategy to achieve standardisation in laboratory medicine aimed at comparable measurement results regardless of the method, the measurement procedure (test kit) and the laboratory where analyses are carried out. Essential tools for the implementation of the concept of measurement traceability in laboratory medicine are reference materials, reference measurement procedures and -one of the biggest challenges -networks of reference laboratories.
The In Vitro Diagnostic Directive (1) of the European Union stipulates that values assigned to calibrators and control materials must be traceable to reference materials and/or reference methods of higher order.
According to the 'Vocabulary in Metrology (VIM)' (2) and the 'Guide to the Expression of Uncertainty in Metrology (GUM)' (3) measurement traceability is defined as property of the result of a measurement Summary: The concept of measurement traceability provides probably the most important strategy to achieve standardisation in laboratory medicine aimed at comparable measurement results regardless of the method, the measurement procedure (test kit) and of the laboratory where analyses are carried out. Establishing networks of reference laboratories is -in addition to reference measurement procedures and reference materialsone of the biggest challenges in implementing the concept of measurement traceability. With respect to these requirements, the Joint Committee on Traceability in Laboratory Medicine (JCTLM), established by the BIPM, the IFCC and the ILAC, has launched two projects in its working groups. WG-1 has to date published tables of reference materials and reference procedures on the BIPM web-sites, whereas WG-2 is identifying reference measurement laboratories. There is general agreement now that reference laboratories should be identified -according to the metrological level of the procedures applied where the principle of measurement is the most important criterion, -on the basis of accreditation or at least compliance with ISO 15195 or ISO 17025 as calibration laboratory, and -on the basis of their ability to demonstrate performance in regular inter-laboratory comparisons (ring trials). To date, a data base on candidate reference laboratories has been collected containing information on the laboratory identity, the metrological level of the procedures and on the status of accreditation and the participation in networks or ring trials. The data base currently contains the addresses of about 60 laboratories. On average, each of the laboratories reported measurement capabilities for six different measurands resulting in about 360 entries. The IFCC has recently launched a ring trial program for reference laboratories for some thirty different measurands. Ring trial results not only demonstrate the competence of individual laboratories, but also reveal the equivalence or bias of different reference procedures. Traceability of a value attributed to a routine sample, a calibrator or a control material is established by a series of comparative measurements using measurement procedures and reference materials in a chain of decreasing hierarchical order as shown in Figure 1 . This is described in detail in ISO standard 17511 (4) . Since each link in the traceability chain contributes to the uncertainty of the result it is advisable to omit as many steps as possible. In terms of metrology it would be ideal to omit all in-between steps of the traceability chain and to measure the routine sample directly by use of a primary reference procedure; this of course is not feasible.
The complete traceability chain as presented here is valid only for those measurable quantities which can have a value expressed in SI units. When primary or secondary calibrators are not available, the traceability chain for many measurands in laboratory medicine ends at a lower level, e.g. at the manufacturer's standing measurement procedure. In a case where a manufacturer detects a new diagnostic marker and defines the measurable quantity by establishing a measurement procedure for this marker, the manufacturer's measurement procedure will form the top of the traceability chain. Nevertheless, even in this simple situation, the principles of the traceability concept are applicable.
An inevitable precondition for establishing traceable results to calibrators and control materials is the specificity of the measurement procedures applied. Results of measurement cannot be traceable when the procedure applied partially detects components which are not consistent with the definition of the measurand.
The implementation of this concept obviously requires reference measurement procedures, reference materials and reference laboratories. With respect to these requirements, the Joint Committee on Traceability in Laboratory Medicine (JCTLM), established by the International Bureau of Weights and Measures (BIPM), the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) and the International Laboratory Accreditation Cooperation (ILAC), has launched two projects in its working groups. WG-1 has to date published tables of reference materials and reference procedures on the BIPM web-sites, whereas WG-2 is identifying reference measurement laboratories (5).
In the hierarchical scheme of laboratories, the National Metrology Institutes form the top level, followed by accredited calibration (reference) laboratories and, finally, the testing (routine) laboratories (Figure 2 ).
There is general agreement now that reference laboratories should be identified To date, a data base on candidate reference laboratories has been collected which currently contains the addresses of about 60 laboratories. On average, each of the laboratories reported measurement capabilities for six different measurands resulting in about 350 to 360 entries.
Laboratories were asked to report details on the measurement principle, the calibrator and the control materials as well as the literature used.
The most common principle of measurement used as reference measurement procedure for the determination of metabolites and substrates, e.g. glucose, creatinine, urea, uric acid, cholesterol and total glycerol was isotope dilution mass spectrometry (IDMS); a small number of laboratories applied an HPLC technique.
Enzymes are usually analysed by the IFCC primary reference procedures; some Japanese laboratories applied national standard methods.
For electrolytes, e.g. sodium or potassium, we find a variety of different metrological principles comprising flame emission and atomic absorption spectrometry, ion chromatography and gravimetry.
Steroid and thyroid hormones as well as therapeutic drugs were exclusively determined by IDMS.
Additional information is requested concerning the status of accreditation or compliance with relevant standards. Currently, only very few laboratories in laboratory medicine are accredited as reference laboratories -or calibration laboratories according to either ISO 15195 or ISO 17025. It should be stressed that ISO 17025 concerns all types of laboratories, routine (testing) and calibration laboratories, and that it contains some separate paragraphs dedicated specifically to calibration laboratories. In the accreditation process it should be emphasised that compliance with the calibration laboratory requirements is essential. ISO 15195 is dedicated particularly to calibration laboratories in laboratory medicine, here called reference laboratories. ISO 15195 uses the terminology of laboratory medicine but the requirements are the same as formulated in ISO 17025 for calibration laboratories.
The management system requirements formulated in ISO 15195 are similar to those requested for any type of laboratory; however, the technical requirements are dedicated to the metrological aspects that have to be observed by laboratories responsible for 'calibration'.
Another section of the questionnaire concerned the frequency of measurements. Surprisingly, one laboratory declared that it performs more than 8000 measurements using IFCC enzyme reference procedures per annum. Considering the efforts necessary in performing reliable reference measurements, there was some doubt in that statement and it turned out that this laboratory actually performed routine measurements using commercial IFCC traceable test procedures.
The last items of the questionnaire concerned the participation in a network or in ring trials. Evidently, the candidate reference laboratories only occasionally performed comparative measurements, e.g. in the IMEP programme or in national networks conducted by a National Metrology Institute. The CCQM offered a small number of ring trials (cholesterol, glucose and creatinine) where only National Metrology Institutes were accepted as participants.
In view of this, in 2003, the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) launched a ring trial program for reference laboratories. Currently, laboratories are asked to register for the second ring trial through a questionnaire in the form of an Excel data sheet.
Ring Trials for Reference Laboratories are offered for some thirty different measurands according to the following rules: a) Ring trials will be offered for the following groups of measurands: -metabolites and substrates, -electrolytes, basic -enzymes, -hormones, -therapeutic drugs. ) Ring trials will be offered regularly (every 6 -12 months), c) The deadline for reporting results after distribution of samples will be five months.
Since reference procedures are laborious and time-consuming it is necessary to allow at least five months for analyses.
Evaluation and reporting by the EQAS organisation will take about one month ensuring that results will be available before the next ring trial is initiated. d) Two different samples will be distributed in each ring trial; results are evaluated as YOUDEN diagrams. e) Each participating laboratory will receive an overall evaluation as well as a report on its individual performance. According to the rules set out by the The rectangles around the dots show the uncertainty for each laboratory JCTLM Executive, results and addresses will no longer be confidential. However, we will offer the participants the possibility to withdraw individual laboratory results for particular measurands one month after a preliminary report of the results and before reporting the data on the web-site. f) Key measurands will be selected for each group of measurands in each ring trial.
This is necessary to collect statistically sound information from the ring trials.
Example:
The EQAS organisation will offer ring trials for all five enzyme activity measurements according to the IFCC 37 °C reference procedures. Due to the workload, not all laboratories will participate for all measurands. At the worst, Lab.A will analyse ALT, Lab.B AST, Lab.C GGT, Lab.D CK and Lab.E LDH. Because of the limited number of participating laboratories it will be difficult to collect a statistically relevant number of results for each of the measurands necessary to demonstrate comparability of results from different laboratories.
Therefore, the EQAS organiser will select one key measurand from each group of measurands for every ring trial occasion. It is highly recommended to provide results for this key measurand. Participation for all other measurands is voluntary. The selected key measurand for each group of measurands will change from one ring trial to the next.
In the first ring trial conducted in October 2003, 28 laboratories registered for various measurands. Of these, 26 sent in their results. As was to be expected, the majority of results were reported for the key measurands, e.g. cholesterol, sodium, ALT and progesterone. In total, 92 pairs of results were received and evaluated in YOUDEN diagrams.
Each dot in a YOUDEN diagram for the measurement of sodium in serum reflects the two results reported from one laboratory, whereby the value for sample A may be read from the abscissa and for sample B from the ordinate (Figure 3) . The grey scales in the diagrams amount to 1% of the mean values. The rectangles around the dots reveal the individual expanded uncertainties.
For sodium, five laboratories used flame emission spectrometry and one laboratory ion chromatography. The small relative standard deviation of the reference laboratory results of about 0.6% among the six laboratories reflects an excellent agreement.
For enzymes, the situation is much more difficult. The results for ALT show a considerable dispersion between the laboratories (2.6 -3.1% rel. standard deviation) as can be shown in Figure 4 . This may be explained by the fact that the enzyme procedures do not use calibrators but are based on absolute measurements of the reaction rates where many inherent types of uncertainties, e.g. from the adjustment of temperature, pH, absorbance and wavelength play an important role. Therefore, the uncertainty of the measurement of enzymes is inevitably larger than for other measurands.
For glucose, only three sets of results were reported ( Figure 5 ). It seems that there is a bias of the laboratory which used the spectrophotometric hexokinase-gluc-6-phosphate dehydrogenase procedure, whereas the two sets of results from IDMS laboratories are in excellent agreement.
For uric acid, four laboratories using IDMS showed excellent agreement, whereas another laboratory performing HPLC showed considerable bias of its results ( Figure 6 ).
From a metrological point of view, the ring trial result for cholesterol was quite interesting. At first glance, there seems to be a considerable dispersion of results (Figure 7) . However, a more detailed inspection shows that there are two groups of results, one from the IDMS laboratories and the second with higher values of the Abell-Kendall users. A statistical evaluation demonstrated an acceptable small relative standard deviation of less than 1% between the IDMS labo- ratories. Among the Abell-Kendall laboratories, the dispersion of results is even smaller. However, a significant bias of almost 3% between the two principles of measurement could be observed.
Although progesterone was announced as a key measurand, only three laboratories were prepared to report results (Figure 8) . Two of them are in good agreement, one came up with considerably lower values, in particular for the sample A.
Also, for digitoxine, only three laboratories reported results, whereby two of them were in good agreement (Figure 9 ).
It can be summarised that the JCTLM will identify reference laboratories on the basis of their status of accreditation or compliance with ISO 15195, on the results of regularly performed ring trials, on the principle of measurement applied. 
